retatrutide joint pain Once-Weekly Reduces Weight and Knee in Patients With Obesity and Osteoarthritis Retatrutide Sets New Benchmark in

The commercial game for positions 2 through 5 in the triple-agonist category is not "match Retatrutide's 28.7%." It is "deliver 20-24% at a materially lower price, with a better tolerability profile, or via an oral formulation that improves compliance." 5.4 The Dysesthesia Signal and What It Implies Mechanistically Retatrutide's TRIUMPH-4 readout reported dysesthesia - abnormal sensory nerve sensations including tingling, burning, or reduced sensation - at 8% on the 9 mg arm and 20.9% on the 12 mg arm

Gandhi, N

Powell-Wiley TM, Poirier P, Burke LE, Despres JP, Gordon-Larsen P, Lavie CJ, et al

This dual mechanism, reduced intake plus increased expenditure, explains why the Phase 2 data showed such dramatically higher weight loss percentages than any dual agonist trial

If dietary measures are insufficient, over-the-counter fiber supplements (psyllium, methylcellulose) or osmotic laxatives (polyethylene glycol) may be appropriate after discussing with your healthcare provider

NN9931-4296 Investigators